COVID-19 and the vaccine: Taking stock of how the Indian government has responded to the pandemic

FP Staff
·4-min read

Nearly eleven months after the novel coronavirus outbreak began in India, there may finally be some cause for cheer €" in the form of the vaccine being developed by AstraZeneca and the University of Oxford.

The vaccine is expected to receive approval by the end of the year, and may be launched in January, according to an article in Mint.

On Saturday, Prime Minister Narendra Modi is slated to visit Ahmedabad, Hyderabad and Pune to review the development of the vaccines against coronavirus. He is scheduled to visit the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune. Two of these sites are where India is indigenously developing vaccines to fight COVID-19 and one of these sites (Ahmedabad) is where the vaccine will be manufactured.

Pune Divisional Commissioner Saurabh Rao has also been quoted as saying by PTI that ambassadors and envoys from 100 countries will visit the Serum Institute of India and the Gennova Biopharmaceuticals Ltd in Pune on 4 December.

Covid-chart-640
Covid-chart-640

In this context, here is an overview of where India stands in the fight against COVID-19 and the steps the government took since Modi announced a nationwide lockdown on 24 March, and a brief look at the status of vaccines under development.

Case load

As of 28 November, India has 6,731 cases per million population, according to the Union health ministry's data. In comparison, USA has 40,000 cases per million, UK has 23,361, France has 33,424, Brazil has 29,129 while Italy has 25,456. Most of these countries have about 4-5 times the number of cases than India, on a per million basis.

When it comes to number of deaths per million population. India saw 98 deaths per million population.€‹ In comparison, the US saw 813, Brazil saw 805, France saw 780, Spain saw 955, UK saw 846 and Italy 888. However, as of 18 November, neighbouring Pakistan and Bangladesh had lower death rates than India, according to an analysis by BBC.

Effect on economy and relief measures

The COVID-19 lockdown also caused immense financial distress across the country. To tide over this, the government announced free food grains and cash payment through the Rs 1.70 lakh crore Pradhan Mantri Garib Kalyan Package (PMGKP), according to the Union finance ministry.

The Indian economy contracted by 7.5 percent in the July-September quarter of this fiscal amid the COVID-19 crisis, official data showed on Friday.

The gross domestic product (GDP) had expanded by 4.4 percent in the corresponding July-September period of 2019-20, according to data released by the National Statistical Office (NSO).

Vaccines

The efficacy of AstraZeneca and Oxford's vaccine, known formally as AZD1222, has varied in trials, depending on the combination of doses administered. The vaccine was found to bring the number of symptomatic COVID-19 cases down by 90 percent in those who received half a dose of the vaccine followed by a full dose a month later. However, the efficacy reduced to 62 percent when the vaccine was administered as two full doses at least a month apart.

An article in The Indian Express quoted K Srinath Reddy, President of the Public Health Foundation of India, as saying, "I would say that it is possible that a lower dose exposure initially primes the system much better, and the second dose takes the body's immune response to a much higher level, but this is speculative."

The Astrazeneca-Oxford vaccine in particular holds out hope for India, as it can be stored at temperatures of 2 degrees Celsius to 8 degrees Celsius and will be priced at USD 3 a dose for the government €" relatively much cheaper than other vaccine candidates.

Meanwhile, Russia's vaccine candidate Sputnik V has claimed efficacy of over 95 percent 42 days after the first dose.

Besides the Oxford-AstraZeneca and the Sputnik V developed by Russia's Gamaleya Research Institute, two other vaccine candidates have also announced their efficacy rates. The Pfizer-BioNTech's BNT162b2 has 95 percent efficacy while Moderna-NIH candidate mRNA-1273 is more than 90 percent effective.

Currently, there are 11 vaccine candidates at the last stage of phase III trials, including the four named above. Overall, as per the latest data released by the WHO on COVID-19 vaccines (last updated on 12 November 2020), there are 48 candidate vaccines undergoing clinical evaluation at various stages, whereas, 164 candidate vaccines are in preclinical evaluation.

With inputs from PTI

Also See: Oxford-Astrazeneca trial data show vaccine is at least 70 percent effective and easy to store as well

Oxford-AstraZeneca COVID-19 vaccine will be available at cost price across world, says pharma head Olivier Nataf

COVID-19 vaccine: Narendra Modi to visit Pune-based Serum Institute of India on 28 November

Read more on Health by Firstpost.